In the EASY-FIT study, atorvastatin 20 mg per day provided a greater increase in fibrous cap thickness in coronary atherosclerotic plaques at 12 months than atorvastatin 5 mg per day. Kenichi Komukai, MD, and colleagues assessed the effect of ... Orthopedics Today, 1 week ago
Atorvastatin at Reperfusion Reduces Myocardial Infarct Size in Mice by Activating eNOS in Bone Marrow-Derived Cells
by Yikui Tian, Joel Linden, Brent A. French, Zequan Yang Background The current study was designed to test our hypothesis that atorvastatin could reduce infarct size in intact mice by activating eNOS, specifically the eNOS in bone marrow-derived ...Plosone.org, 2 weeks ago
Studies from Shanghai Jiao-Tong University Have Provided New Information about Clinical Trials and Studies [Effects of atorvastatin on bone mineral...
Studies from Shanghai Jiao-Tong University Have Provided New Information about Clinical Trials and Studies [Effects of atorvastatin on bone mineral density (BMD) and bone metabolism in elderly males with osteopenia and mild dyslipidemia: A ...] ...4 Traders, 2 weeks ago
Assessment of hepatic function, oxidant/antioxidant status, and histopathological changes in rats treated with atorvastatin: Effect of dose and acute intoxication with acetaminophen
Effect of dose and acute intoxication with acetaminophen MM Farag 1 ⇑ MB Mohamed 1 EA Youssef 2 1 Department of Pharmacology, Medical Research Institute, Alexandria University, Alexandria, Egypt 2 Department of Cell Biology, Medical ...Human And Experimental Toxicology, 3 weeks ago
Effect of Atorvastatin Therapy on FibrousCap Thickness in Coronary Atherosclerotic Plaque as Assessed byOptical CoherenceTomography The EASY-FIT Study
Background The detailed mechanism of plaque stabilization by statin therapy is not fully understood. Objectives The aim of this study was to assess the effect of lipid-lowering therapy with 20 mg/day of atorvastatin versus 5 mg/day of atorvastatin ...Journal of the American College of Cardiology, 3 weeks ago
Comparison of the Efficacy of Rosuvastatin versus Atorvastatin in Preventing Contrast Induced Nephropathy in Patient with Chronic Kidney Disease Undergoing Percutaneous Coronary Intervention
by Yong Liu, Yuan-hui Liu, Ning Tan, Ji-yan Chen, Ying-ling Zhou, Li-wen Li, Chong-yang Duan, Ping-Yan Chen, Jian-fang Luo, Hua-long Li, Wei-Guo Objectives We prospectively compared the preventive effects of rosuvastatin and atorvastatin on ...Plosone.org, 1 month ago
Summary Vascepa stayed on the preferred lists of the top 3 PBMs (Express Scripts, CVS/Caremark, and Catamaran), despite the presence of Lovaza generics since April. About a third of the largest 25 insurers have Vascepa on their Medicare and state ...Seeking Alpha, 1 day ago
4412758 A major Indian biotechnology company just announced it is breaking into the exciting field of biologic medicines. Zydus-Cadila has successfully manufactured a rough copy of a popular autoimmune disease biologic called Humira. The firm has ...Daily Caller, 1 day ago
Despite an apparant hefty increase in R&D outlay, a number of large pharma firms also hauled back on clinical investment The top 30 pharma companies spent a combined total of $112 billion on research and development last year. Calculated to be ...Pharmafocus, 1 day ago Top 30 Pharmas spent $112 billion on R&D in 2013; report Pharma Letter, 1 day ago
on your WebpageAdd Widget >Get your members hooked!